Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) R1 compared induction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results